ACS Nano · 2015 · 144 citations · 48 references
EngineeringImmunologyBiomedical EngineeringImmunotherapyAdoptive ImmunotherapySynthetic ImmunologyNanomedicineTumor ImmunologyNeo-epitope ResponsesAntibody EngineeringRadiation OncologyCell TransplantationTherapeutic VaccineTumor TargetingCell EngineeringTumor MicroenvironmentVaccinationDurable RegressionCancer ImmunosurveillanceImmunomodulationVaccine DesignMedicine
Adoptive immunotherapy (AIT) can mediate durable regression of cancer, but widespread adoption of AIT is limited by the cost and complexity of generating tumor-specific T cells. Here we develop an Enrichment + Expansion strategy using paramagnetic, nanoscale artificial antigen presenting cells (aAPC) to rapidly expand tumor-specific T cells from rare naïve precursors and predicted neo-epitope responses. Nano-aAPC are capable of enriching rare tumor-specific T cells in a magnetic column and subsequently activating them to induce proliferation. Enrichment + Expansion resulted in greater than 1000-fold expansion of both mouse and human tumor-specific T cells in 1 week, with nano-aAPC based enrichment conferring a proliferation advantage during both in vitro culture and after adoptive transfer in vivo. Robust T cell responses were seen not only for shared tumor antigens, but also for computationally predicted neo-epitopes. Streamlining the rapid generation of large numbers of tumor-specific T cells in a cost-effective fashion through Enrichment + Expansion can be a powerful tool for immunotherapy.
48
Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens
Matthew M. Gubin, Xiuli Zhang, Heiko Schuster et al. · Nature · 2014 · 2K citations · Full text
Cancer Immunotherapy Based on Mutation-Specific CD4+ T Cells in a Patient with Epithelial Cancer
Eric Tran, Simon Turcotte, Alena Gros et al. · Science · 2014 · 1.7K citations · Full text